APO Research
Talk to an analyst

APO RESEARCH · REPORT

Malaria Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Malaria Vaccines Market Outlook and Growth Opportunities 2026

22 December 2025218 pages

Choose your research edition.

Industry ResearchMalaria Vaccines Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal Malaria Vaccines Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Malaria Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Malaria Vaccines Market Outlook and Growth Opportunities 2026218 pages · $4,250 USDMarket Analysis & ForecastGlobal Malaria Vaccines Market Analysis and Forecast 2026-2032216 pages · $4,950 USD

Market perspective

The global Malaria Vaccines market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Malaria Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Malaria Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Malaria Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Malaria Vaccines market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Malaria Vaccines market include Sanofi, Novartis AG, Mylan N.V., Pfizer Inc, GlaxoSmithKline Plc, Zydus Cadila, VLP Therapeutics, Taj Pharmaceuticals Limited and Sun Pharmaceutical Industries Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Malaria Vaccines market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Malaria Vaccines and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Malaria Vaccines revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Malaria Vaccines market.

Malaria Vaccines Segment by Company

Sanofi

Novartis AG

Mylan N.V.

Pfizer Inc

GlaxoSmithKline Plc

Zydus Cadila

VLP Therapeutics

Taj Pharmaceuticals Limited

Sun Pharmaceutical Industries Ltd

Sumaya Biotech

Strides Pharma Science Limited

Sanaria Inc

OSIVAX

Nobelpharma Co

Lupin

Ipca Laboratories Ltd

Hikma Pharmaceuticals PLC

GeoVax

GenVec

Cipla Inc

CellFree Sciences

Bliss GVS Pharma Ltd

Amneal Pharmaceuticals LLC

AJANTA PHARMA

AdvaCare Pharma

Actiza Pharmaceutical Private Limited

Malaria Vaccines Segment by Type

Erythrocytic Vaccine

Pre-Erythrocytic Vaccine

Multi-antigen Vaccine

Malaria Vaccines Segment by Application

Clinics

Hospitals

Community Centers

Malaria Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Malaria Vaccines status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Malaria Vaccines key companies, revenue, market share, and recent developments.

3. To split the Malaria Vaccines breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Malaria Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Malaria Vaccines significant trends, drivers, influence factors in global and regions.

6. To analyze Malaria Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Malaria Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Malaria Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Malaria Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Malaria Vaccines industry.

Chapter 3: Detailed analysis of Malaria Vaccines company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Malaria Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Malaria Vaccines in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Malaria Vaccines Industry Trends Table 2. Malaria Vaccines Industry Drivers Table 3. Malaria Vaccines Industry Opportunities and Challenges Table 4. Malaria Vaccines Industry Restraints Table 5. Global Malaria Vaccines Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Malaria Vaccines Revenue Share by Company (2021-2026) Table 7. Global Malaria Vaccines Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Malaria Vaccines Key Company Manufacturing Base & Headquarters Table 9. Global Malaria Vaccines Company, Product Type & Application Table 10. Global Malaria Vaccines Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Malaria Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Erythrocytic Vaccine Table 15. Significant Companies of Pre-Erythrocytic Vaccine Table 16. Significant Companies of Multi-antigen Vaccine Table 17. Global Malaria Vaccines Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Malaria Vaccines Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Malaria Vaccines Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Malaria Vaccines Sales Value Share by Type (2021-2026) Table 21. Global Malaria Vaccines Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Clinics Table 23. Significant Companies of Hospitals Table 24. Significant Companies of Community Centers Table 25. Global Malaria Vaccines Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Malaria Vaccines Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Malaria Vaccines Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Malaria Vaccines Sales Value Share by Application (2021-2026) Table 29. Global Malaria Vaccines Sales Value Share by Application (2027-2032) Table 30. Global Malaria Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Malaria Vaccines Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Malaria Vaccines Sales Value Share by Region (2021-2026) Table 33. Global Malaria Vaccines Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Malaria Vaccines Sales Value Share by Region (2027-2032) Table 35. Global Malaria Vaccines Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Malaria Vaccines Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Malaria Vaccines Sales Value Market Share by Country (2021-2026) Table 38. Global Malaria Vaccines Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Malaria Vaccines Sales Value Market Share by Country (2027-2032) Table 40. Sanofi Company Information Table 41. Sanofi Business Overview Table 42. Sanofi Malaria Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Sanofi Malaria Vaccines Product Portfolio Table 44. Sanofi Recent Development Table 45. Novartis AG Company Information Table 46. Novartis AG Business Overview Table 47. Novartis AG Malaria Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Novartis AG Malaria Vaccines Product Portfolio Table 49. Novartis AG Recent Development Table 50. Mylan N.V. Company Information Table 51. Mylan N.V. Business Overview Table 52. Mylan N.V. Malaria Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Mylan N.V. Malaria Vaccines Product Portfolio Table 54. Mylan N.V. Recent Development Table 55. Pfizer Inc Company Information Table 56. Pfizer Inc Business Overview Table 57. Pfizer Inc Malaria Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Pfizer Inc Malaria Vaccines Product Portfolio Table 59. Pfizer Inc Recent Development Table 60. GlaxoSmithKline Plc Company Information Table 61. GlaxoSmithKline Plc Business Overview Table 62. GlaxoSmithKline Plc Malaria Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. GlaxoSmithKline Plc Malaria Vaccines Product Portfolio Table 64. GlaxoSmithKline Plc Recent Development Table 65. Zydus Cadila Company Information Table 66. Zydus Cadila Business Overview Table 67. Zydus Cadila Malaria Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Zydus Cadila Malaria Vaccines Product Portfolio Table 69. Zydus Cadila Recent Development Table 70. VLP Therapeutics Company Information Table 71. VLP Therapeutics Business Overview Table 72. VLP Therapeutics Malaria Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. VLP Therapeutics Malaria Vaccines Product Portfolio Table 74. VLP Therapeutics Recent Development Table 75. Taj Pharmaceuticals Limited Company Information Table 76. Taj Pharmaceuticals Limited Business Overview Table 77. Taj Pharmaceuticals Limited Malaria Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Taj Pharmaceuticals Limited Malaria Vaccines Product Portfolio Table 79. Taj Pharmaceuticals Limited Recent Development Table 80. Sun Pharmaceutical Industries Ltd Company Information Table 81. Sun Pharmaceutical Industries Ltd Business Overview Table 82. Sun Pharmaceutical Industries Ltd Malaria Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Sun Pharmaceutical Industries Ltd Malaria Vaccines Product Portfolio Table 84. Sun Pharmaceutical Industries Ltd Recent Development Table 85. Sumaya Biotech Company Information Table 86. Sumaya Biotech Business Overview Table 87. Sumaya Biotech Malaria Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Sumaya Biotech Malaria Vaccines Product Portfolio Table 89. Sumaya Biotech Recent Development Table 90. Strides Pharma Science Limited Company Information Table 91. Strides Pharma Science Limited Business Overview Table 92. Strides Pharma Science Limited Malaria Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. Strides Pharma Science Limited Malaria Vaccines Product Portfolio Table 94. Strides Pharma Science Limited Recent Development Table 95. Sanaria Inc Company Information Table 96. Sanaria Inc Business Overview Table 97. Sanaria Inc Malaria Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. Sanaria Inc Malaria Vaccines Product Portfolio Table 99. Sanaria Inc Recent Development Table 100. OSIVAX Company Information Table 101. OSIVAX Business Overview Table 102. OSIVAX Malaria Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 103. OSIVAX Malaria Vaccines Product Portfolio Table 104. OSIVAX Recent Development Table 105. Nobelpharma Co Company Information Table 106. Nobelpharma Co Business Overview Table 107. Nobelpharma Co Malaria Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 108. Nobelpharma Co Malaria Vaccines Product Portfolio Table 109. Nobelpharma Co Recent Development Table 110. Lupin Company Information Table 111. Lupin Business Overview Table 112. Lupin Malaria Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 113. Lupin Malaria Vaccines Product Portfolio Table 114. Lupin Recent Development Table 115. Ipca Laboratories Ltd Company Information Table 116. Ipca Laboratories Ltd Business Overview Table 117. Ipca Laboratories Ltd Malaria Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 118. Ipca Laboratories Ltd Malaria Vaccines Product Portfolio Table 119. Ipca Laboratories Ltd Recent Development Table 120. Hikma Pharmaceuticals PLC Company Information Table 121. Hikma Pharmaceuticals PLC Business Overview Table 122. Hikma Pharmaceuticals PLC Malaria Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 123. Hikma Pharmaceuticals PLC Malaria Vaccines Product Portfolio Table 124. Hikma Pharmaceuticals PLC Recent Development Table 125. GeoVax Company Information Table 126. GeoVax Business Overview Table 127. GeoVax Malaria Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 128. GeoVax Malaria Vaccines Product Portfolio Table 129. GeoVax Recent Development Table 130. GenVec Company Information Table 131. GenVec Business Overview Table 132. GenVec Malaria Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 133. GenVec Malaria Vaccines Product Portfolio Table 134. GenVec Recent Development Table 135. Cipla Inc Company Information Table 136. Cipla Inc Business Overview Table 137. Cipla Inc Malaria Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 138. Cipla Inc Malaria Vaccines Product Portfolio Table 139. Cipla Inc Recent Development Table 140. CellFree Sciences Company Information Table 141. CellFree Sciences Business Overview Table 142. CellFree Sciences Malaria Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 143. CellFree Sciences Malaria Vaccines Product Portfolio Table 144. CellFree Sciences Recent Development Table 145. Bliss GVS Pharma Ltd Company Information Table 146. Bliss GVS Pharma Ltd Business Overview Table 147. Bliss GVS Pharma Ltd Malaria Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 148. Bliss GVS Pharma Ltd Malaria Vaccines Product Portfolio Table 149. Bliss GVS Pharma Ltd Recent Development Table 150. Amneal Pharmaceuticals LLC Company Information Table 151. Amneal Pharmaceuticals LLC Business Overview Table 152. Amneal Pharmaceuticals LLC Malaria Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 153. Amneal Pharmaceuticals LLC Malaria Vaccines Product Portfolio Table 154. Amneal Pharmaceuticals LLC Recent Development Table 155. AJANTA PHARMA Company Information Table 156. AJANTA PHARMA Business Overview Table 157. AJANTA PHARMA Malaria Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 158. AJANTA PHARMA Malaria Vaccines Product Portfolio Table 159. AJANTA PHARMA Recent Development Table 160. AdvaCare Pharma Company Information Table 161. AdvaCare Pharma Business Overview Table 162. AdvaCare Pharma Malaria Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 163. AdvaCare Pharma Malaria Vaccines Product Portfolio Table 164. AdvaCare Pharma Recent Development Table 165. Actiza Pharmaceutical Private Limited Company Information Table 166. Actiza Pharmaceutical Private Limited Business Overview Table 167. Actiza Pharmaceutical Private Limited Malaria Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 168. Actiza Pharmaceutical Private Limited Malaria Vaccines Product Portfolio Table 169. Actiza Pharmaceutical Private Limited Recent Development Table 170. Research Programs/Design for This Report Table 171. Authors List of This Report Table 172. Secondary Sources Table 173. Primary Sources List of Figures Figure 1. Malaria Vaccines Product Image Figure 2. Global Malaria Vaccines Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Malaria Vaccines Market Size (2021-2032) & (US$ Million) Figure 4. Global Malaria Vaccines Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Erythrocytic Vaccine Image Figure 8. Pre-Erythrocytic Vaccine Image Figure 9. Multi-antigen Vaccine Image Figure 10. Global Malaria Vaccines Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Malaria Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Malaria Vaccines Sales Value Share by Type (2021-2032) Figure 13. Clinics Image Figure 14. Hospitals Image Figure 15. Community Centers Image Figure 16. Global Malaria Vaccines Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Malaria Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Malaria Vaccines Sales Value Share by Application (2021-2032) Figure 19. Global Malaria Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Malaria Vaccines Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Malaria Vaccines Sales Value (2021-2032) & (US$ Million) Figure 22. North America Malaria Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Malaria Vaccines Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Malaria Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Malaria Vaccines Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Malaria Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Malaria Vaccines Sales Value (2021-2032) & (US$ Million) Figure 28. South America Malaria Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Malaria Vaccines Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Malaria Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Malaria Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Malaria Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Malaria Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Malaria Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Malaria Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Malaria Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Malaria Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Malaria Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Malaria Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Malaria Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Malaria Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Malaria Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Malaria Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Malaria Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Malaria Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Malaria Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Malaria Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Malaria Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Malaria Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Malaria Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Malaria Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Malaria Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Malaria Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Malaria Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Malaria Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Malaria Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Malaria Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Malaria Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Malaria Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Malaria Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Malaria Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Malaria Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Malaria Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Malaria Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Malaria Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Malaria Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Malaria Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Malaria Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Malaria Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Malaria Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Malaria Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Malaria Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Malaria Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Malaria Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Malaria Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Malaria Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Malaria Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Malaria Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Malaria Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Malaria Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Malaria Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Malaria Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Malaria Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Malaria Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Malaria Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Malaria Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Malaria Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Malaria Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Malaria Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Malaria Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Malaria Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Malaria Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Malaria Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Malaria Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Malaria Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Malaria Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Malaria Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Malaria Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Malaria Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Malaria Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Malaria Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Malaria Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Malaria Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Malaria Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Malaria Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Malaria Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Malaria Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Malaria Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Malaria Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Malaria Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Malaria Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Malaria Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Malaria Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Malaria Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Erythrocytic Vaccine
  • Pre-Erythrocytic Vaccine
  • Multi-antigen Vaccine
Applications
  • Clinics
  • Hospitals
  • Community Centers
Companies covered
  • Sanofi
  • Novartis AG
  • Mylan N.V.
  • Pfizer Inc
  • GlaxoSmithKline Plc
  • Zydus Cadila
  • VLP Therapeutics
  • Taj Pharmaceuticals Limited
  • Sun Pharmaceutical Industries Ltd
  • Sumaya Biotech
  • Strides Pharma Science Limited
  • Sanaria Inc
  • OSIVAX
  • Nobelpharma Co
  • Lupin
  • Ipca Laboratories Ltd
  • Hikma Pharmaceuticals PLC
  • GeoVax
  • GenVec
  • Cipla Inc
  • CellFree Sciences
  • Bliss GVS Pharma Ltd
  • Amneal Pharmaceuticals LLC
  • AJANTA PHARMA
  • AdvaCare Pharma
  • Actiza Pharmaceutical Private Limited

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Malaria Vaccines Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Malaria Vaccines Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Malaria Vaccines Market Dynamics
  1. 2.1 Malaria Vaccines Industry Trends
  2. 2.2 Malaria Vaccines Industry Drivers
  3. 2.3 Malaria Vaccines Industry Opportunities and Challenges
  4. 2.4 Malaria Vaccines Industry Restraints
3 Malaria Vaccines Market by Company
  1. 3.1 Global Malaria Vaccines Company Revenue Ranking in 2025
  2. 3.2 Global Malaria Vaccines Revenue by Company (2021-2026)
  3. 3.3 Global Malaria Vaccines Company Ranking (2024-2026)
  4. 3.4 Global Malaria Vaccines Company Manufacturing Base and Headquarters
  5. 3.5 Global Malaria Vaccines Company Product Type and Application
  6. 3.6 Global Malaria Vaccines Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Malaria Vaccines Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Malaria Vaccines Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Malaria Vaccines Market by Type
  1. 4.1 Malaria Vaccines Type Introduction
  2. 4.1.1 Erythrocytic Vaccine
  3. 4.1.2 Pre-Erythrocytic Vaccine
  4. 4.1.3 Multi-antigen Vaccine
  5. 4.2 Global Malaria Vaccines Sales Value by Type
  6. 4.2.1 Global Malaria Vaccines Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Malaria Vaccines Sales Value by Type (2021-2032)
  8. 4.2.3 Global Malaria Vaccines Sales Value Share by Type (2021-2032)
5 Malaria Vaccines Market by Application
  1. 5.1 Malaria Vaccines Application Introduction
  2. 5.1.1 Clinics
  3. 5.1.2 Hospitals
  4. 5.1.3 Community Centers
  5. 5.2 Global Malaria Vaccines Sales Value by Application
  6. 5.2.1 Global Malaria Vaccines Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Malaria Vaccines Sales Value by Application (2021-2032)
  8. 5.2.3 Global Malaria Vaccines Sales Value Share by Application (2021-2032)
6 Malaria Vaccines Regional Value Analysis
  1. 6.1 Global Malaria Vaccines Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Malaria Vaccines Sales Value by Region (2021-2032)
  3. 6.2.1 Global Malaria Vaccines Sales Value by Region: 2021-2026
  4. 6.2.2 Global Malaria Vaccines Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Malaria Vaccines Sales Value (2021-2032)
  7. 6.3.2 North America Malaria Vaccines Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Malaria Vaccines Sales Value (2021-2032)
  10. 6.4.2 Europe Malaria Vaccines Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Malaria Vaccines Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Malaria Vaccines Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Malaria Vaccines Sales Value (2021-2032)
  16. 6.6.2 South America Malaria Vaccines Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Malaria Vaccines Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Malaria Vaccines Sales Value Share by Country, 2025 VS 2032
7 Malaria Vaccines Country-level Value Analysis
  1. 7.1 Global Malaria Vaccines Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Malaria Vaccines Sales Value by Country (2021-2032)
  3. 7.2.1 Global Malaria Vaccines Sales Value by Country (2021-2026)
  4. 7.2.2 Global Malaria Vaccines Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Malaria Vaccines Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Malaria Vaccines Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Malaria Vaccines Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Malaria Vaccines Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Malaria Vaccines Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Malaria Vaccines Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Malaria Vaccines Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Malaria Vaccines Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Malaria Vaccines Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Malaria Vaccines Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Malaria Vaccines Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Malaria Vaccines Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Malaria Vaccines Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Malaria Vaccines Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Malaria Vaccines Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Malaria Vaccines Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Malaria Vaccines Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Malaria Vaccines Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Malaria Vaccines Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Malaria Vaccines Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Malaria Vaccines Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Malaria Vaccines Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Malaria Vaccines Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Malaria Vaccines Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Malaria Vaccines Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Malaria Vaccines Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Malaria Vaccines Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Malaria Vaccines Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Malaria Vaccines Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Malaria Vaccines Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Malaria Vaccines Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Malaria Vaccines Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Malaria Vaccines Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Malaria Vaccines Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Malaria Vaccines Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Malaria Vaccines Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Malaria Vaccines Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Malaria Vaccines Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Malaria Vaccines Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Malaria Vaccines Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Malaria Vaccines Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Malaria Vaccines Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Malaria Vaccines Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Malaria Vaccines Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Malaria Vaccines Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Malaria Vaccines Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Malaria Vaccines Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Malaria Vaccines Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Malaria Vaccines Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Malaria Vaccines Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Malaria Vaccines Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Malaria Vaccines Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Malaria Vaccines Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Malaria Vaccines Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Malaria Vaccines Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Malaria Vaccines Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Malaria Vaccines Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Malaria Vaccines Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Malaria Vaccines Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Malaria Vaccines Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Malaria Vaccines Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Malaria Vaccines Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Malaria Vaccines Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Malaria Vaccines Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Malaria Vaccines Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Malaria Vaccines Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Malaria Vaccines Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Malaria Vaccines Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Malaria Vaccines Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Malaria Vaccines Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Malaria Vaccines Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Malaria Vaccines Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Malaria Vaccines Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Malaria Vaccines Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Malaria Vaccines Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Malaria Vaccines Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Malaria Vaccines Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Malaria Vaccines Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Malaria Vaccines Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Malaria Vaccines Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Malaria Vaccines Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Malaria Vaccines Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Malaria Vaccines Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Malaria Vaccines Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Malaria Vaccines Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Malaria Vaccines Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Novartis AG
  8. 8.2.1 Novartis AG Company Information
  9. 8.2.2 Novartis AG Business Overview
  10. 8.2.3 Novartis AG Malaria Vaccines Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis AG Malaria Vaccines Product Portfolio
  12. 8.2.5 Novartis AG Recent Developments
  13. 8.3 Mylan N.V.
  14. 8.3.1 Mylan N.V. Company Information
  15. 8.3.2 Mylan N.V. Business Overview
  16. 8.3.3 Mylan N.V. Malaria Vaccines Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Mylan N.V. Malaria Vaccines Product Portfolio
  18. 8.3.5 Mylan N.V. Recent Developments
  19. 8.4 Pfizer Inc
  20. 8.4.1 Pfizer Inc Company Information
  21. 8.4.2 Pfizer Inc Business Overview
  22. 8.4.3 Pfizer Inc Malaria Vaccines Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Inc Malaria Vaccines Product Portfolio
  24. 8.4.5 Pfizer Inc Recent Developments
  25. 8.5 GlaxoSmithKline Plc
  26. 8.5.1 GlaxoSmithKline Plc Company Information
  27. 8.5.2 GlaxoSmithKline Plc Business Overview
  28. 8.5.3 GlaxoSmithKline Plc Malaria Vaccines Revenue and Gross Margin (2021-2026)
  29. 8.5.4 GlaxoSmithKline Plc Malaria Vaccines Product Portfolio
  30. 8.5.5 GlaxoSmithKline Plc Recent Developments
  31. 8.6 Zydus Cadila
  32. 8.6.1 Zydus Cadila Company Information
  33. 8.6.2 Zydus Cadila Business Overview
  34. 8.6.3 Zydus Cadila Malaria Vaccines Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Zydus Cadila Malaria Vaccines Product Portfolio
  36. 8.6.5 Zydus Cadila Recent Developments
  37. 8.7 VLP Therapeutics
  38. 8.7.1 VLP Therapeutics Company Information
  39. 8.7.2 VLP Therapeutics Business Overview
  40. 8.7.3 VLP Therapeutics Malaria Vaccines Revenue and Gross Margin (2021-2026)
  41. 8.7.4 VLP Therapeutics Malaria Vaccines Product Portfolio
  42. 8.7.5 VLP Therapeutics Recent Developments
  43. 8.8 Taj Pharmaceuticals Limited
  44. 8.8.1 Taj Pharmaceuticals Limited Company Information
  45. 8.8.2 Taj Pharmaceuticals Limited Business Overview
  46. 8.8.3 Taj Pharmaceuticals Limited Malaria Vaccines Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Taj Pharmaceuticals Limited Malaria Vaccines Product Portfolio
  48. 8.8.5 Taj Pharmaceuticals Limited Recent Developments
  49. 8.9 Sun Pharmaceutical Industries Ltd
  50. 8.9.1 Sun Pharmaceutical Industries Ltd Company Information
  51. 8.9.2 Sun Pharmaceutical Industries Ltd Business Overview
  52. 8.9.3 Sun Pharmaceutical Industries Ltd Malaria Vaccines Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Sun Pharmaceutical Industries Ltd Malaria Vaccines Product Portfolio
  54. 8.9.5 Sun Pharmaceutical Industries Ltd Recent Developments
  55. 8.10 Sumaya Biotech
  56. 8.10.1 Sumaya Biotech Company Information
  57. 8.10.2 Sumaya Biotech Business Overview
  58. 8.10.3 Sumaya Biotech Malaria Vaccines Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Sumaya Biotech Malaria Vaccines Product Portfolio
  60. 8.10.5 Sumaya Biotech Recent Developments
  61. 8.11 Strides Pharma Science Limited
  62. 8.11.1 Strides Pharma Science Limited Company Information
  63. 8.11.2 Strides Pharma Science Limited Business Overview
  64. 8.11.3 Strides Pharma Science Limited Malaria Vaccines Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Strides Pharma Science Limited Malaria Vaccines Product Portfolio
  66. 8.11.5 Strides Pharma Science Limited Recent Developments
  67. 8.12 Sanaria Inc
  68. 8.12.1 Sanaria Inc Company Information
  69. 8.12.2 Sanaria Inc Business Overview
  70. 8.12.3 Sanaria Inc Malaria Vaccines Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Sanaria Inc Malaria Vaccines Product Portfolio
  72. 8.12.5 Sanaria Inc Recent Developments
  73. 8.13 OSIVAX
  74. 8.13.1 OSIVAX Company Information
  75. 8.13.2 OSIVAX Business Overview
  76. 8.13.3 OSIVAX Malaria Vaccines Revenue and Gross Margin (2021-2026)
  77. 8.13.4 OSIVAX Malaria Vaccines Product Portfolio
  78. 8.13.5 OSIVAX Recent Developments
  79. 8.14 Nobelpharma Co
  80. 8.14.1 Nobelpharma Co Company Information
  81. 8.14.2 Nobelpharma Co Business Overview
  82. 8.14.3 Nobelpharma Co Malaria Vaccines Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Nobelpharma Co Malaria Vaccines Product Portfolio
  84. 8.14.5 Nobelpharma Co Recent Developments
  85. 8.15 Lupin
  86. 8.15.1 Lupin Company Information
  87. 8.15.2 Lupin Business Overview
  88. 8.15.3 Lupin Malaria Vaccines Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Lupin Malaria Vaccines Product Portfolio
  90. 8.15.5 Lupin Recent Developments
  91. 8.16 Ipca Laboratories Ltd
  92. 8.16.1 Ipca Laboratories Ltd Company Information
  93. 8.16.2 Ipca Laboratories Ltd Business Overview
  94. 8.16.3 Ipca Laboratories Ltd Malaria Vaccines Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Ipca Laboratories Ltd Malaria Vaccines Product Portfolio
  96. 8.16.5 Ipca Laboratories Ltd Recent Developments
  97. 8.17 Hikma Pharmaceuticals PLC
  98. 8.17.1 Hikma Pharmaceuticals PLC Company Information
  99. 8.17.2 Hikma Pharmaceuticals PLC Business Overview
  100. 8.17.3 Hikma Pharmaceuticals PLC Malaria Vaccines Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Hikma Pharmaceuticals PLC Malaria Vaccines Product Portfolio
  102. 8.17.5 Hikma Pharmaceuticals PLC Recent Developments
  103. 8.18 GeoVax
  104. 8.18.1 GeoVax Company Information
  105. 8.18.2 GeoVax Business Overview
  106. 8.18.3 GeoVax Malaria Vaccines Revenue and Gross Margin (2021-2026)
  107. 8.18.4 GeoVax Malaria Vaccines Product Portfolio
  108. 8.18.5 GeoVax Recent Developments
  109. 8.19 GenVec
  110. 8.19.1 GenVec Company Information
  111. 8.19.2 GenVec Business Overview
  112. 8.19.3 GenVec Malaria Vaccines Revenue and Gross Margin (2021-2026)
  113. 8.19.4 GenVec Malaria Vaccines Product Portfolio
  114. 8.19.5 GenVec Recent Developments
  115. 8.20 Cipla Inc
  116. 8.20.1 Cipla Inc Company Information
  117. 8.20.2 Cipla Inc Business Overview
  118. 8.20.3 Cipla Inc Malaria Vaccines Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Cipla Inc Malaria Vaccines Product Portfolio
  120. 8.20.5 Cipla Inc Recent Developments
  121. 8.21 CellFree Sciences
  122. 8.21.1 CellFree Sciences Company Information
  123. 8.21.2 CellFree Sciences Business Overview
  124. 8.21.3 CellFree Sciences Malaria Vaccines Revenue and Gross Margin (2021-2026)
  125. 8.21.4 CellFree Sciences Malaria Vaccines Product Portfolio
  126. 8.21.5 CellFree Sciences Recent Developments
  127. 8.22 Bliss GVS Pharma Ltd
  128. 8.22.1 Bliss GVS Pharma Ltd Company Information
  129. 8.22.2 Bliss GVS Pharma Ltd Business Overview
  130. 8.22.3 Bliss GVS Pharma Ltd Malaria Vaccines Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Bliss GVS Pharma Ltd Malaria Vaccines Product Portfolio
  132. 8.22.5 Bliss GVS Pharma Ltd Recent Developments
  133. 8.23 Amneal Pharmaceuticals LLC
  134. 8.23.1 Amneal Pharmaceuticals LLC Company Information
  135. 8.23.2 Amneal Pharmaceuticals LLC Business Overview
  136. 8.23.3 Amneal Pharmaceuticals LLC Malaria Vaccines Revenue and Gross Margin (2021-2026)
  137. 8.23.4 Amneal Pharmaceuticals LLC Malaria Vaccines Product Portfolio
  138. 8.23.5 Amneal Pharmaceuticals LLC Recent Developments
  139. 8.24 AJANTA PHARMA
  140. 8.24.1 AJANTA PHARMA Company Information
  141. 8.24.2 AJANTA PHARMA Business Overview
  142. 8.24.3 AJANTA PHARMA Malaria Vaccines Revenue and Gross Margin (2021-2026)
  143. 8.24.4 AJANTA PHARMA Malaria Vaccines Product Portfolio
  144. 8.24.5 AJANTA PHARMA Recent Developments
  145. 8.25 AdvaCare Pharma
  146. 8.25.1 AdvaCare Pharma Company Information
  147. 8.25.2 AdvaCare Pharma Business Overview
  148. 8.25.3 AdvaCare Pharma Malaria Vaccines Revenue and Gross Margin (2021-2026)
  149. 8.25.4 AdvaCare Pharma Malaria Vaccines Product Portfolio
  150. 8.25.5 AdvaCare Pharma Recent Developments
  151. 8.26 Actiza Pharmaceutical Private Limited
  152. 8.26.1 Actiza Pharmaceutical Private Limited Company Information
  153. 8.26.2 Actiza Pharmaceutical Private Limited Business Overview
  154. 8.26.3 Actiza Pharmaceutical Private Limited Malaria Vaccines Revenue and Gross Margin (2021-2026)
  155. 8.26.4 Actiza Pharmaceutical Private Limited Malaria Vaccines Product Portfolio
  156. 8.26.5 Actiza Pharmaceutical Private Limited Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst